In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Our Top Ten Items from a Year Most Want to Forget

Executive Summary

From the bear market, to the growing management credibility gap, to GPO whistleblowers, 2002 was a year most of us are glad to have behind us. But within the gloom, some glimmers of hope: most important among them is a sense of directionality at athe FDA following the appointment of a new commissioner.
Advertisement

Related Content

Is Group Purchasing Broke?
Vulnerable Plaque: Medical Device's New Biological Frontier
At NASS: Let the (Biologics) Revolution Begin
Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?
An FDA Nominee, Biologics Reviews Move to CDER
Vulnerable Plaque Heats Up
Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?
Pfizer's Balancing Act
GPOs Cry Foul Following Senate Hearings

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel